Theravance Biopharma First Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Theravance Biopharma | 10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
Theravance Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 106.61% HC Wainwright & Co. → $20 Reiterates Buy → Buy 04/12/2024 116.94% BTIG → $21 Initiates
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q1 2024 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript:Financial Performance:Theravance Biopharma reported Q1 net sales of $55.2 million in partnership wi
Buy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug Prospects
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours
Theravance Biopharma (TBPH) Monday night reported a Q1 net loss of $0.24 per share, compared with $0.35 loss a year ago. Analysts polled by Capital IQ expected $0.25 loss. Revenue for the quarter ende
Express News | Theravance Biopharma Inc: Limited Cash Burn Expected in 2024
Express News | Theravance Biopharma Inc: Continues to Expect Non-Gaap Net Loss in First Half of 2024 and to Approach Non-Gaap Breakeven in Second Half of 2024
Express News | Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, Vs. Street Est of $14M
04:10 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, vs. Street Est of $14M
Express News | Theravance Biopharma Q1 Adjusted Net Income USD -4.544 Million Vs. Ibes Estimate USD -12.5 Million
Express News | Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Theravance Biopharma Q1 Operating Income USD -11.207 Million
Theravance Biopharma 1Q Loss/Shr 24c >TBPH
Theravance Biopharma 1Q Loss/Shr 24c >TBPH
Notable Earnings After Monday's Close
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at...
Strong Week for Theravance Biopharma (NASDAQ:TBPH) Shareholders Doesn't Alleviate Pain of Five-year Loss
Theravance Biopharma, Inc. (NASDAQ:TBPH) shareholders should be happy to see the share price up 13% in the last week. But don't envy holders -- looking back over 5 years the returns have been reall